Vaxcyte
PCVX
125 hedge funds and large institutions have $1.45B invested in Vaxcyte in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 27 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
85% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 27
33% more capital invested
Capital invested by funds: $1.09B → $1.45B (+$362M)
18% more funds holding
Funds holding: 106 → 125 (+19)
14.66% more ownership
Funds ownership: 88.21% → 102.87% (+15%)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
42% less call options, than puts
Call options by funds: $7.95M | Put options by funds: $13.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$123M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.1M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$22.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.9M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$20.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.76M |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$9.68M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$6.84M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$6.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GTCM
126
Gyon Technologies Capital Management
Denville,
New Jersey
| – | -$590K | -27,105 | Closed |
|
|
BFM
127
Boothbay Fund Management
New York
| – | -$495K | -22,733 | Closed |
|
|
TI
128
Trexquant Investment
Stamford,
Connecticut
| – | -$367K | -16,851 | Closed |
|
129
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$301K | -13,820 | Closed |
|
130
Voloridge Investment Management
Jupiter,
Florida
| – | -$271K | -12,475 | Closed |
|
|
C
131
Covestor
London,
United Kingdom
| – | -$25 | -1 | -10% |
|
|
PA
132
Parallel Advisors
San Francisco,
California
| – | +$279 | +11 | New |
|
PCVX Hedge Fund Activity: Q3 2022 in Review
125 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2022, worth a combined $1.45B — up 33% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PCVX positions and 7 closed out — a net gain of 19 holders — while 50 added to existing stakes and 27 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $123M. The largest seller was OrbiMed, cutting an estimated $20.2M.
- 125 institutional investors held Vaxcyte (PCVX) as of Q3 2022, up from 106 in Q2 2022.
- Funds reported $1.45B of Vaxcyte stock for Q3 2022, up 33% quarter-over-quarter.
- 26 funds opened new Vaxcyte positions in Q3 2022 and 7 closed out, a net change of +19 holders.
- The largest Vaxcyte buyer in Q3 2022 was Janus Henderson Group, an estimated $123M added.
- The largest Vaxcyte seller in Q3 2022 was OrbiMed, an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2022.